Abstract: The purpose of the study was to investigate the clinical effect of a clinical pharmacist (CP) intervention upon admission to hospital on inpatient harm and to assess a potential educational bias. Over 16 months, 593 adult patients taking ≥4 medications daily were included from three Danish acute medicine wards. Patients were randomized to either the CP intervention or the usual care (prospective control). To assess a potential educational bias, a retrospective control group was formed by randomization. The CP intervention comprised medication history, medication reconciliation, medication review and entry of proposed prescriptions into the electronic prescribing system. The primary outcome of inpatient harm was identified using triggers from the Institute of Healthcare Improvement Global Trigger Tool. Harms were validated and rated for severity by two independent and blinded outcome panels. Secondary end-points were harms per patient, length of hospital stay, readmissions and 1-year mortality. Harm affected 11% of the patients in the intervention group compared to 17% in the combined control group, odds ratio (OR) 0.57 (CI 0.32-1.02, p = 0.06). The incidence of harm was similar in the intervention and prospective control groups, OR 0.80 (CI 0.40-1.59, p = 0.52) but occurred less frequently in the intervention than in the retrospective control group OR 0.46 (CI 0.25-0.85, p = 0.01). An educational bias from the intervention to the control group might have contributed to this negative outcome. In conclusion, the CP intervention at admission to hospital had no statistically significant effect on inpatient harm.
Involving clinical pharmacists (CPs) in drug therapy is perceived as an effective means of improving inpatient care [1] [2] [3] . However, rigorously designed studies with clinical outcome are sparse despite that higher-quality studies are needed to determine the most effective approaches to optimize inpatient medication processes [3] [4] [5] . Only few randomized controlled trials (RCTs) have investigated the clinical outcome of pharmacist interventions [6, 7] . In two studies, a reduction in length of stay (LOS) and drug-related readmissions were reported [8, 9] , while another study reported no significant impact on clinical outcome [10] . In one RCT, the effect of a combined pharmacist-pharmacologist intervention came out insignificant as well [11] . Clinical pharmaceutical services hold the potential to reduce the incidence of adverse drug events (ADEs) [12] that represent a major hospital care problem. Although the incidences may vary across different settings, ADEs appear to be a considerable problem and in worst case some are lethal [13] [14] [15] [16] [17] [18] [19] [20] [21] . Conventional means such as voluntary incident reports, record reviews and observational databases [21] seem to detect <10% of all ADEs [18, 22, 23] . Consequently, trigger tools have been developed [17, 18, 23] that identify harm or injury to patients rather than potential risk [12] . Using these tools, studies have identified ADEs in 18-33% of inpatients [18, 24, 25] . Likewise, frequent causes of errors have been identified [13, 20, 26, 27] .
Although widely implemented, neither the clinical effect nor the impact on in-hospital ADEs of CP services in the acute wards has been studied in RCTs. Furthermore, none of the previous RCTs on the impact of in-hospital clinical pharmaceutical service have captured the potential effects of educational bias or contamination bias that might lead to an underestimation of the true effect of an intervention comprising close collaboration of pharmacists and other healthcare professionals who cannot be blinded to the presence of a pharmacist.
Consequently, this RCT was set up to investigate the clinical effect of a CP intervention upon admission to acute medicine wards on in-hospital patient harm and secondly to estimate a potential educational bias from the intervention to the control group. from one geriatric ward, no hospitals in this region had established CP services, but the majority of the wards had established a pharmaconomist top-up service [28] and all wards had access to a CPoperated telephone service at the regional hospital pharmacy.
Screening and randomization. Patients were screened by the CPs upon arrival to the acute wards, on weekdays between 8:00 and 17:00. Medical patients aged 18 years or older taking four or more medications a day (including over-the-counter medicines and dietary supplements) were eligible provided they had a Danish social security number and were able to give consent in Danish. Patients admitted for palliative or terminal care and patients who needed physician attendance within the first hour of admission were not included. Patients were excluded if they were discharged, transferred to intensive care or deceased within 24 hr of admission. Additionally, patients who were transferred directly from other hospitals in the region or had already received a pharmacist intervention were excluded.
For the first 8 months, the CPs were alternately absent for 2 months (retrospective periods) and present for 2 months (prospective periods) at the wards, giving two 2-month periods at each centre with no CP present. After these 8 months, the CPs were present at all three wards for the remaining time. In the retrospective periods, patients were included for a second, retrospective control group, which would allow the assessment of a potential educational bias from the intervention to the prospective control group. The inclusion criteria and screening conditions for the retrospective control group were similar with the exception that no patient consent was required.
In the prospective periods, the patients were stratified by centre and randomized to the intervention or the prospective control using computer-generated block randomization with a block size of six. In the retrospective periods, the patients were randomized similarly to either the retrospective control group or exclusion with an allocation ratio so that the retrospective control group matched the size of the prospective control group.
Randomization lists were generated using a computer-based randomization tool [29] and kept at the hospital pharmacy by the pharmacist responsible for clinical trials. Allocation was revealed to the CP by telephone whenever the CP had enrolled a patient.
Pharmacist intervention. Three CPs performed the interventions, all of whom had a master's degree in pharmacy and more than 2 years of clinical experience. The intervention comprised secondary medication history, medication reconciliation, medication review based on the pre-admission medication, and entry of proposed prescriptions in the electronic medication module (EMM). The intervention was made before a physician attended to the patient and entered admission medication orders into the EMM. In 98% of cases, the intervention was made within a few hours of admission. Details of the intervention are described elsewhere [30] . After the intervention, the patients received standard hospital care and were not met by the CP later in their hospital stay. The control group patients received standard hospital care with no CP involvement.
Data collection. The medical records containing physicians' notes, medication information and laboratory data were collected as a copy for each patient's admission period. Nurses' notes were available in a few cases as well. Demographic data such as age, gender, number of drugs and medical history were recorded for all included patients. The LOS was recorded using the discharge day or the day of death if the patient died during admission. In a 1-year follow-up, data on the time to, and number of, all-cause readmissions and deaths were collected from the electronic patient records. A readmission was defined as any hospital admission in the region after the index admission.
Outcome. The primary outcome was the proportion of patients with harm as indicated by one or more medication-related triggers. The methodology of using triggers to identify patient harm has been described by the Institute of Healthcare Improvement (IHI) [12, 31, 32] . The trigger tool for identifying ADEs in this study was adapted from validated tools in the following way; using the Danish version of the IHI Global Trigger Tool (GTT) as base, the triggers corresponding to the ADE triggers identified by Rozich et al. [18, 32] were extracted, resulting in a list of 25 triggers (table 1) .
For the assessment of the primary outcome, a trigger panel and two outcome panels, all blinded to the allocation of patients, were formed. The trigger panel consisted of two nurses, with 7 and 15 years of clinical experience, both trained in GTT as a whole and in the selected medication triggers in particular. The nurses independently reviewed the medical records of all included patients and recorded all triggers. The patients' records were reviewed in the same order determined by a pre-made, randomized list. For each trigger, the nurses recorded whether patient harm had occurred. Disagreements were solved by discussion, and for each patient, a consensus on triggers and preliminary category of harm was reached. Harm was categorized using the index of the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) [33] . The NCC MERP index categories of harm range from E (temporary harm requiring intervention) to I (harm causing patient death).
The nurses were sought blinded to the patients' allocation by removing all CP entries in the nurses' copies of the medical record. In a few cases (<10), however, physicians' recordings of actual CP encounters could not be removed.
Subsequently, all cases associated with category E-I harm were assessed independently by two outcome panels, one Danish and one Swedish. Each outcome panel consisted of an internal medicine senior consultant and an experienced CP from outside Region Zealand.
The clinical panels that were blinded to the allocation by removing all pharmacist entries from the medical record copies were presented with a case summary of each incidence of harm identified by the trigger panel. The full medical records, except from the pharmacist entries, were at their disposal if needed. Using the NCC MERP index, the outcome panels assessed each incidence of harm regarding severity, relation to medication, preventability by the hospital care as a whole and preventability by the applied CP intervention. Only incidences categorized as E-I by both outcome panels were considered harm in the final registration. If the panels categorized the harm A-D, this incidence was categorized as non-harm. In case of inconsistency, the lowest category rated by the panels was used. Figure 1 presents an overview of the review process. Success of blinding was tested by asking all panel members whether they thought that each patient needed, did not need or already had had a pharmacist's medication review during the admission.
Statistical analysis. Sample size calculation was based on the inhospital ADE incidence of 20-30% reported by Rozich et al. [18] . To detect a 50% reduction in ADEs from 20% to 10%, with 80% statistical power and a of 5%, 507 patients should be enrolled. With a ratio of 1:2 between the intervention and the control groups, 169 patients should be enrolled in each group. Assuming a dropout rate of approximately 20%, the sample size was raised to 600.
Inter-rater agreement between the outcome panels and between the review nurses was tested using Cohen's Kappa statistics. Comparison of the intervention group and the control groups was made using logistic regression analysis for binary responses, Poisson regression with log-link for incidences and Cox regression for survival data. A p-value of 0.05 or less was considered statistically significant.
The primary analysis compared the intervention group to the combined control group. The secondary analysis compared the intervention group to each of the control groups separately.
In the primary analyses, the following potential confounding variables were included in the logistic and Poisson regression models: age, gender, centre, medical history (cardiac, respiratory, endocrine, musculoskeletal or gastrointestinal diagnoses) and number of medications in the medication history. The variables were analysed using manual backwards deletion of non-significant confounders. Both unadjusted and adjusted statistics were reported. For patients who were transferred to a ward with established CP care, the admission periods were censored at the time of transfer. Patients who were included at a later readmission and patients transferred to a ward with established CP care were excluded from the analysis of 1-year follow-up on readmissions and death.
All statistical analyses were performed in IBM SPSS Statistics for Windows, version 20.0.0 (IBM Corp. Released 2011, Armonk, NY, USA).
Results
The inclusion began in March 2010 and ended in July 2011. In the trial period, 593 patients were included. Subsequently, 95 patients were excluded from the analyses, mainly due to discharge within 24 hr. Of the 498 patients, 340 were allocated to the control groups and 158 to the intervention group. Figure 2 shows the study flow of patients, and table 2 gives the baseline characteristics.
Generally, the intervention group and control groups were balanced at baseline. The proportion of patients aged 70 years or older, however, was significantly larger in the intervention group (table 2) .
Triggers and harm.
In 373 (75%) of the patients, the trigger panel identified 1066 triggers, 142 of which were deemed as having caused harm in the E-I category. In 132 of the 142 cases, both outcome panels agreed on harm in the E-I category [distributed on 76 patients (15%)].
The inter-rater agreement showed high agreement between the trigger panel members regarding triggers (j = 0.63, p < 0.001). Agreement between the trigger panel and outcome panels (j = 0.70, p < 0.001) and between the two outcome panels (j = 0.61, p < 0.001) [34] regarding the categorization of patient harm according to the NCC MERP index was similar. Figure 3 shows the distribution of harms by category and by group.
The outcome panels considered 40% and 61% of the harms, respectively, to be medication-related with a moderate interrater agreement (j = 0.56, p < 0.001). The panels considered 28% and 40%, respectively, of the harms preventable by the hospital care as a whole (j = 0.43, p < 0.001), and 14% and 4%, respectively, preventable by the described intervention (j = 0.20, p = 0.003).
Success of blinding assessments revealed that the nurses guessed on CP interventions in 8% of intervention group patients, while the outcome panels identified no cases with CP intervention.
Primary outcome. Table 3 presents an overview of the identified triggers and harms by the allocation groups.
The proportion of patients with harm in the intervention group (10.8%) was lower and borderline statistically significant compared to the combined control group (17.1%), odds ratio (OR) 0.57 (95% CI 0.32-1.02, p = 0.06) (table 4) . Adjusted for confounders, the OR was 0.56 (95% CI 0.31-1.01, p = 0.05). None of the variables in the multivariate analysis had individually significant influence on the effect in the manual backwards deletion of non-significant confounders.
Secondary outcome.
The secondary outcome measures are summed in table 4. Significantly fewer harms per patient occurred in the intervention group compared to the combined control groups, but the groups did not differ regarding the 1-year follow-up. 
Secondary analyses.
Comparison of the intervention group to each of the control groups allowed investigation of a possible educational bias (table 5) . No statistically significant effect was found comparing the intervention group to the prospective control group. The intervention group and the retrospective control group, however, differed statistically significantly in terms of proportion of patients with harm, number of harms per patient and mortality in the 1-year follow-up.
Discussion
To the best of our knowledge, this is the first RCT addressing the effect of a CP intervention in acute wards on inpatient harm. Although the analysis of the primary outcome measure revealed that the proportion of patients with harm was lower in the intervention group, the result was not statistically significant. The secondary outcome, the number of harms per patient, however, was lower in the intervention group. Furthermore, no effect of the intervention could be detected on the median LOS, the readmission rate or mortality.
Clinical outcome.
The patients in the intervention group tended to have a positive outcome in all of the in-hospital clinical results (triggers and harms per patient, proportion of patients with harm, severity of harm and LOS). Hitherto, one RCT has demonstrated a significant reduction in LOS in patients who had a comprehensive integrated medicines management (IMM) service by CPs during the hospital stay [9] , while another RCT reported no effect on LOS of a combined pharmacist-pharmacologist intervention at admission to hospital [35] .
Despite that no other RCT has measured the impact of CP intervention on in-hospital patient harm, other RCTs on the impact of comprehensive in-hospital pharmacist interventions Table 4 . Primary analysis, displayed as unadjusted and adjusted for confounders (centre, age, sex, number of drugs in medication history and a medical history of lung, heart, endocrine, gastrointestinal and muscular diagnoses). 1 Logistic regression analysis, effects in odds ratio. 2 Poisson regression analysis, effects in incidence rates. 3 Cox regression analysis, effects in hazard ratios. [8] [9] [10] . The present study showed no effect of the intervention on any of the follow-up measures including readmission rates and death within the first year after discharge. Furthermore, this study was not powered to detect the smaller differences in the secondary outcome such as readmission and mortality. Our intervention, however, was less comprehensive and was applied only at the first hours of the admission, hence focusing on reducing inpatient harm. Thus, it is unclear whether adding more elements of the comprehensive IMM to CP intervention at the admission is sufficient to have significant positive impact on in-hospital patient harm.
Educational bias.
The secondary analyses unveiled a statistically significant effect of our intervention on harm as compared to the retrospective control group. This might indicate contamination or educational bias between the prospectively enrolled groups. Although the retrospective control group was formed in the periods where no CP was present in the wards, confounders may have contributed to the result. Still, patients regardless of allocation group were attended to by the same personnel that may have learned from the intervention and applied the same principles to patients in the prospective control group. As it is impossible to conceal the presence of a CP dedicated to optimize the medication process, the general focus on medication problems might have been increased. Up till now, no study has tried to assess the size of educational bias, which is a general problem in this type of studies [6, 7] . An educational bias may, at least partly, explain why it is difficult in RCTs to show a positive effect of CP interventions. Thus, two recent reviews of in-hospital medication review both found that the number of RCTs was few (5 and 10, respectively) and all were prone to contamination and educational bias [6, 7] .
The primary outcome focus in this study was the in-hospital ADEs detected with the Adverse Drug Event Trigger Tool [18] that aims at the in-hospital ADEs in a broad sense and is not restricted to specific drugs, diseases or patient groups. Moreover, it focuses on ADEs that actually reach the patients in contrast to potential ADEs. The ADE triggers were extracted from the Danish version of the GTT to utilize a previously validated tool. GTT was originally developed to measure patient safety over time within an organization. Recently, a number of studies questioning the applicability of GTT have been published [25, 36, 37] . The studies found large inter-rater variability suggesting that training, procedures and documentation should be standardized. In the present study, a trigger panel of only two nurses independently reviewed the patient records. The inter-rater agreement was substantial even before they reached consensus on the harm categorization. The nurses were trained simultaneously, and they reviewed all patient records in the same order. Furthermore, the inter-rater agreement between the trigger panel and the outcome panels and between the two outcome panels was both substantial as well. It is unlikely that the trigger tool identifies all possible ADEs. As this affects all incidences regardless of allocation group, group comparisons are still valid.
Strengths and limitations.
This is the first study to investigate CPs' impact on in-hospital ADEs in a prospective, multi-centre RCT. Among the strengths are the prospective, randomized design, the use of a validated trigger tool, assessment by independent and blinded panels, a long follow-up and the attempt to assess the magnitude of the educational bias.
Nevertheless, the study has important limitations to consider. To ensure that day-to-day variance in level of care was balanced between the groups, we used stratified block randomization. Still, we cannot exclude that lack of concealment has affected the enrolment and randomization. Neither the CPs nor the healthcare personnel or patients were blinded to the patient allocation. The patients were informed of their allocation on request, although few actually asked. On the other hand, both the trigger panel and the outcome panels were blinded and blinding appears to have been quite successful for all the panels.
Only three CPs performed the study intervention, which took place in three hospitals within the same Danish region, and it might be difficult to generalize the results to other clinical settings.
The study was designed to detect a 50% reduction of harm in the intervention group compared to the combined control groups. The power calculation did not take into account the marked educational bias, and hence, the study might be slightly underpowered. While the use of a retrospective control group allowed us to assess the educational bias, it has profound limitations as well in terms of variation in patient characteristics. For example, the retrospectively enrolled patients could have been more ill even though this was not reflected in the recorded patients' baseline characteristics or length of hospital stay. A way to overcome this drawback is cluster randomization [7] at ward level which on the other hand would have introduced a problem with casemix and variation of usual care across the wards. Furthermore, while the exclusion criteria of admission <24 hr were chosen as the CP intervention was unlikely to be implemented before that, this was the major reason for exclusion of patients in the analysis. Finding triggers and harm during a <24-hr admission is seldom, and the effect of the CP intervention will probably be less if an intention-to-treat analysis was performed.
Finally, this study investigated a relatively simple intervention compared to the comprehensive pharmacist interventions applied in other RCTs [8] [9] [10] . Nevertheless, the applied CP intervention in this study is relatively low resource and simple to implement. No effect in the follow-up period of readmissions or death was found. Yet, it does tend to have a positive impact on in-hospital clinical outcome. The magnitude of a CP service needed to have a significant, and clinical relevant impact should be targeted by future studies. Thus, it is unclear whether all elements of the comprehensive IMM are effective or whether the CP intervention at the admission is sufficient to achieve a significant impact on in-hospital clinical outcome.
Conclusion
This prospective RCT did not show a statistically significant effect of CP intervention on inpatient harm. As educational bias might have diluted the intervention effect, we recommend future studies of this type of CP intervention to incorporate measures to address or assess this type of bias.
